ArticleBMC infectious diseases2017
Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- The epidemiology of hepatitis b virus infection in Uganda after two decades of vaccination: a meta-analysis and meta-regression.BMC infectious diseases · 2025Pooled it
- Pooled it
- Prevalence and socio-demographic factors associated with transfusion transmissible infections among voluntary blood donors in Kigali, Rwanda.BMC infectious diseases · 2026Article
- Viral hepatitis B co-infection among people living with HIV: a National cross-sectional survey in Togo in 2023.BMC infectious diseases · 2025Article
- Vaccination Coverage of People Living with HIV: Before and after Interventional Action.Vaccines · 2024Article
- Prevalence of hepatitis B and C infection and linkage to care among patients with Non-Communicable Diseases in three rural Rwandan districts: a retrospective cross-sectional study.BMC infectious diseases · 2024Article
- Article
- Article
- Long-term effect of chronic hepatitis B on mortality in HIV-infected persons in a differential HBV transmission setting.BMC infectious diseases · 2022Article
- Article
- Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020.Archives of public health = Archives belges de sante publique · 2021Article
- Predictors of vaccination rates in people living with HIV followed at a specialty care clinic.Human vaccines & immunotherapeutics · 2021Article
- Seroprevalence and risk factors of hepatitis B, C and D virus infection amongst patients with features of hepatitis in a referral hospital in Botswana: A cross-sectional study.Southern African journal of infectious diseases · 2021Article
- Article
- Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.BMC public health · 2020Article
- Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy.Clinical microbiology reviews · 2020Review
- Risk factors associated with hepatitis B and C in rural population of Burera district, Rwanda.The Pan African medical journal · 2020Article
- Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program.BMC infectious diseases · 2019Article
- Article
- Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda.BMC infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B (HBV) and C (HCV) are important causes of morbidity and mortality in people living with human immunodeficiency virus (HIV). The burden of these co-infections in sub-Saharan Africa is still unclear. We estimated the prevalence of the hepatitis B surface antigen (HBsAg) and hepatitis C antibody (HCVAb) among HIV-infected individuals in Rwanda and identified factors associated with infection.
methodsBetween January 2016 and June 2016, we performed systematic screening for HBsAg and HCVAb among HIV-positive individuals enrolled at public and private HIV facilities across Rwanda. Results were analyzed to determine marker prevalence and variability by demographic factors.
resultsOverall, among 117,258 individuals tested, the prevalence of HBsAg and HCVAb was 4.3% (95% confidence interval [CI] (4.2-4.4) and 4.6% (95% CI 4.5-4.7) respectively; 182 (0.2%) HIV+ individuals were co-infected with HBsAg and HCVAb. Prevalence was higher in males (HBsAg, 5.4% [5.1-5.6] vs. 3.7% [3.5-3.8]; HCVAb, 5.0% [4.8-5.2] vs. 4.4% [4.3-4.6]) and increased with age; HCVAb prevalence was significantly higher in people aged ≥65 years (17.8% [16.4-19.2]). Prevalence varied geographically.
conclusionHBV and HCV co-infections are common among HIV-infected individuals in Rwanda. It is important that viral hepatitis prevention and treatment activities are scaled-up to control further transmission and reduce the burden in this population. Particular efforts should be made to conduct targeted screening of males and the older population. Further assessment is required to determine rates of HBV and HCV chronicity among HIV-infected individuals and identify effective strategies to link individuals to care and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.